Compare SEE & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEE | IMVT |
|---|---|---|
| Founded | 1960 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.8B |
| IPO Year | 1996 | 2019 |
| Metric | SEE | IMVT |
|---|---|---|
| Price | $42.15 | $27.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $43.50 | $33.00 |
| AVG Volume (30 Days) | ★ 2.8M | 1.5M |
| Earning Date | 05-05-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ 89.50 | N/A |
| EPS | ★ 3.43 | N/A |
| Revenue | ★ $5,359,800,000.00 | N/A |
| Revenue This Year | $1.93 | N/A |
| Revenue Next Year | $2.27 | N/A |
| P/E Ratio | $12.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.34 | $13.36 |
| 52 Week High | $44.27 | $30.09 |
| Indicator | SEE | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 65.73 | 55.03 |
| Support Level | $41.79 | $24.63 |
| Resistance Level | $42.21 | $29.67 |
| Average True Range (ATR) | 0.08 | 1.28 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 100.00 | 42.18 |
Sealed Air Corp is a provider of packaging solutions that integrate sustainable, high-performance materials, automation, equipment, and services. The company designs, manufactures, and delivers packaging solutions that preserve food, protect goods, and automate packaging processes. It delivers its packaging solutions to an array of end markets including fresh proteins, foods, fluids and liquids, medical and life science, e-commerce retail, logistics and omnichannel fulfillment operations, and industrials. It has two reportable segments, Food and Protective. The company generates majority of its revenue from the food segment.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.